TDMS Study 05004-04 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) FURAN NTP Experiment-Test: 05004-04 Report: PEIRPT05 Study Type: CHRONIC Date: 09/03/94 Route: GAVAGE Time: 02:49:52 Facility: Southern Research Institute Chemical CAS #: 110-00-9 Lock Date: None Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 Early Deaths Moribund 16 16 35 Natural Death 1 1 Dead 4 8 11 Dosing Accident 1 Survivors Terminal Sacrifice 28 25 2 Dead 1 Other 1 Animals Examined Microscopically 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (50) (50) (50) Squamous Cell Papilloma 1 (2%) Gallbladder (49) (49) (43) Intestine Small, Duodenum (49) (47) (45) Polyp Adenomatous 1 (2%) Intestine Small, Ileum (48) (47) (44) Liver (50) (50) (50) Carcinoma 1 (2%) Hemangiosarcoma 1 (2%) Hepatocellular Carcinoma 2 (4%) 6 (12%) 22 (44%) Hepatocellular Carcinoma, Multiple, Two 4 (8%) Hepatocellular Carcinoma, Multiple, Three 1 (2%) Hepatocellular Adenoma 5 (10%) 17 (34%) 8 (16%) Hepatocellular Adenoma, Multiple, Two 8 (16%) 4 (8%) Hepatocellular Adenoma, Multiple, Three 4 (8%) 10 (20%) Hepatocellular Adenoma, Multiple, Four 2 (4%) 4 (8%) Hepatocellular Adenoma, Multiple, Five 8 (16%) Hepatocellular Adenoma, Multiple, Greater Than Five 14 (28%) Sarcoma, Metastatic 1 (2%) Sarcoma Stromal, Metastatic, Uterus 1 (2%) Mesentery (24) (27) (4) Carcinoma, Metastatic, Liver 1 (4%) Hemangiosarcoma 1 (4%) Hepatocellular Carcinoma, Metastatic, Liver 1 (25%) Sarcoma, Metastatic 1 (4%) 1 (4%) Sarcoma Stromal, Metastatic, Uterus 1 (4%) Pancreas (50) (49) (50) Carcinoma, Metastatic, Liver 1 (2%) Page 2 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Sarcoma, Metastatic 1 (2%) 1 (2%) Sarcoma Stromal, Metastatic, Uterus 1 (2%) Salivary Glands (50) (50) (50) Adventitia, Hemangioma 1 (2%) Stomach, Forestomach (50) (49) (49) Mucosa, Squamous Cell Papilloma 2 (4%) 6 (12%) 3 (6%) Stomach, Glandular (49) (49) (50) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Gland, Cortex (50) (50) (50) Extra Adrenal Tissue, Carcinoma, Metastatic, Liver 1 (2%) Subcapsular, Adenoma 1 (2%) Adrenal Gland, Medulla (50) (50) (50) Pheochromocytoma Benign 2 (4%) 1 (2%) 3 (6%) Pheochromocytoma Benign, Multiple 3 (6%) Islets, Pancreatic (50) (50) (50) Carcinoma 1 (2%) Pituitary Gland (49) (47) (46) Adenoma 1 (2%) Pars Distalis, Adenoma 25 (51%) 18 (38%) 9 (20%) Pars Distalis, Carcinoma 1 (2%) Pars Intermedia, Adenoma 1 (2%) Thyroid Gland (50) (50) (50) Follicular Cell, Adenoma 2 (4%) 3 (6%) 1 (2%) Follicular Cell, Adenoma, Multiple, Two 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Tissue NOS (1) (1) Abdominal, Sarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (49) (49) (50) Cystadenoma, Papillary 1 (2%) Granulosa Cell Tumor Benign 1 (2%) Granulosa-Theca Tumor Benign 1 (2%) Page 3 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Periovarian Tissue, Carcinoma, Metastatic, Liver 1 (2%) Oviduct (4) (4) (1) Carcinoma, Metastatic, Liver 1 (25%) Uterus (50) (50) (50) Hemangiosarcoma 1 (2%) Sarcoma Stromal 2 (4%) Endometrium, Polyp Stromal 1 (2%) 4 (8%) Endometrium, Polyp Stromal, Multiple 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Blood (1) (1) Bone Marrow (50) (50) (50) Hemangiosarcoma 1 (2%) Lymph Node (50) (50) (50) Lymph Node, Bronchial (21) (29) (21) Lymph Node, Mandibular (47) (46) (48) Lymph Node, Mediastinal (41) (45) (43) Lymph Node, Mesenteric (49) (49) (49) Spleen (50) (50) (50) Hemangiosarcoma 1 (2%) 2 (4%) Thymus (46) (46) (45) Epithelial Cell, Thymoma Benign 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (49) (50) (48) Adenocarcinoma 2 (4%) 1 (2%) 3 (6%) Carcinoma 1 (2%) Skin (50) (50) (50) Squamous Cell Carcinoma 1 (2%) Head, Sebaceous Gland, Adenoma 1 (2%) Sebaceous Gland, Adenoma 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Sarcoma 1 (2%) Subcutaneous Tissue, Sarcoma, Metastatic 1 (2%) Tail, Squamous Cell Papilloma 1 (2%) Tail, Subcutaneous Tissue, Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (3) (2) Abdominal, Sarcoma 1 (50%) Diaphragm, Sarcoma, Metastatic 1 (50%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) Meningioma Benign 1 (2%) Peripheral Nerve (1) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) Adenocarcinoma, Multiple, Metastatic, Greater Than Five, Mammary Gland 1 (2%) Alveolar/Bronchiolar Adenoma 3 (6%) 4 (8%) 3 (6%) Alveolar/Bronchiolar Carcinoma 2 (4%) 2 (4%) 1 (2%) Hemangiosarcoma 1 (2%) Hepatocellular Carcinoma, Multiple, Metastatic, Three, Liver 1 (2%) Hepatocellular Carcinoma, Multiple, Metastatic, Four, Liver 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) Sarcoma, Metastatic 1 (2%) Parenchyma, Mediastinum, Carcinoma, Metastatic, Liver 1 (2%) Nose (50) (50) (50) Trachea (50) (50) (50) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (4) (6) (4) Adenoma 2 (50%) 4 (67%) 2 (50%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (49) Urinary Bladder (50) (50) (50) Page 5 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) Lymphoma Malignant Lymphocytic 3 (6%) 3 (6%) Lymphoma Malignant Mixed 17 (34%) 11 (22%) 7 (14%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 43 43 50 Total Primary Neoplasms 83 101 124 Total Animals with Benign Neoplasms 34 38 48 Total Benign Neoplasms 48 71 82 Total Animals with Malignant Neoplasms 30 24 32 Total Malignant Neoplasms 35 30 42 Total Animals with Metastatic Neoplasms 4 2 3 Total Metastatic Neoplasm 7 12 4 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 Early Deaths Moribund 16 24 24 Dead 1 5 8 Natural Death 1 1 Dosing Accident 2 Accident 1 Survivors Terminal Sacrifice 33 17 16 Other 1 Animals Examined Microscopically 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (50) (48) (44) Adenocarcinoma, Metastatic, Liver 1 (2%) Intestine Small, Duodenum (49) (49) (48) Adenocarcinoma, Metastatic, Uncertain Primary Site 1 (2%) Serosa, Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Intestine Small, Jejunum (50) (49) (48) Adenocarcinoma 1 (2%) Liver (50) (50) (50) Adenocarcinoma, Metastatic, Uncertain Primary Site 1 (2%) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Carcinoma, Multiple, Metastatic, Harderian Gland 1 (2%) Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%) Hemangiosarcoma, Multiple, Two 2 (4%) Hemangiosarcoma, Multiple, Three 1 (2%) Hepatoblastoma 1 (2%) Hepatocellular Carcinoma 5 (10%) 26 (52%) 27 (54%) Hepatocellular Carcinoma, Multiple 2 (4%) Hepatocellular Carcinoma, Multiple, Two 1 (2%) 3 (6%) 5 (10%) Hepatocellular Carcinoma, Multiple, Three 1 (2%) 1 (2%) Hepatocellular Carcinoma, Multiple, Four 1 (2%) Hepatocellular Carcinoma, Two 1 (2%) Hepatocellular Adenoma 18 (36%) 16 (32%) 12 (24%) Hepatocellular Adenoma, Multiple, Two 1 (2%) 8 (16%) 11 (22%) Hepatocellular Adenoma, Multiple, Three 6 (12%) 8 (16%) Page 8 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Hepatocellular Adenoma, Multiple, Four 1 (2%) 4 (8%) Hepatocellular Adenoma, Multiple, Five 1 (2%) 2 (4%) Hepatocellular Adenoma, Multiple, Greater Than Five 1 (2%) 3 (6%) Hepatocellular Adenoma, Two 1 (2%) 2 (4%) Hepatocholangiocarcinoma 2 (4%) Ito Cell Tumor Benign 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Biliary Tract, Adenocarcinoma 2 (4%) 2 (4%) Mesentery (6) (10) (3) Adenocarcinoma, Multiple, Metastatic, Uncertain Primary Site 1 (10%) Adenocarcinoma, Multiple, Metastatic, Greater Than Five, Liver 1 (33%) Adenocarcinoma, Metastatic, Liver 2 (20%) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (10%) Carcinoma, Metastatic, Harderian Gland 1 (10%) Hemangiosarcoma 1 (17%) Hepatocellular Carcinoma, Metastatic, Liver 1 (10%) Hepatocholangiocarcinoma, Multiple, Metastatic, Liver 1 (10%) Sarcoma, Metastatic, Uncertain Primary Site 1 (10%) Pancreas (50) (50) (50) Adenocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Salivary Glands (50) (50) (48) Stomach, Forestomach (49) (50) (50) Mucosa, Squamous Cell Papilloma 1 (2%) 3 (6%) Stomach, Glandular (49) (50) (50) Carcinoid Tumor Malignant 1 (2%) 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Tooth (43) (36) (32) Peridontal Tissue, Carcinoma, Metastatic, Harderian Gland 1 (3%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Carcinoma, Multiple, Metastatic, Harderian Gland 1 (2%) Hemangiosarcoma 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Page 9 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Gland, Cortex (50) (50) (50) Adenoma 2 (4%) 1 (2%) Carcinoma, Metastatic, Harderian Gland 1 (2%) Extra Adrenal Tissue, Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Subcapsular, Adenoma 3 (6%) 2 (4%) Subcapsular, Adenoma, Multiple 1 (2%) Adrenal Gland, Medulla (49) (50) (50) Pheochromocytoma Benign 5 (10%) 7 (14%) Pheochromocytoma Benign, Multiple 1 (2%) 1 (2%) 3 (6%) Pituitary Gland (50) (44) (48) Pars Distalis, Adenoma 1 (2%) Pars Intermedia, Adenoma 1 (2%) Thyroid Gland (50) (50) (50) Follicular Cell, Adenoma 1 (2%) Follicular Cell, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ductus Deferens (1) (2) Epididymis (50) (50) (50) Preputial Gland (6) (6) (5) Adenoma 1 (17%) Prostate (49) (50) (50) Seminal Vesicle (50) (50) (50) Adenocarcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Testes (50) (50) (50) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) Hemangiosarcoma 2 (4%) 1 (2%) Lymph Node (50) (50) (49) Lymph Node, Bronchial (14) (27) (26) Lymph Node, Mandibular (49) (48) (43) Lymph Node, Mediastinal (38) (45) (41) Page 10 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Adenocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Lymph Node, Mesenteric (50) (50) (48) Adenocarcinoma, Metastatic, Liver 1 (2%) Spleen (50) (50) (49) Adenocarcinoma, Metastatic, Liver 1 (2%) Hemangiosarcoma 3 (6%) 2 (4%) Thymus (42) (44) (42) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (50) (50) (50) Fibrosarcoma 1 (2%) Squamous Cell Papilloma 1 (2%) Subcutaneous Tissue, Fibroma 3 (6%) Subcutaneous Tissue, Fibrosarcoma 3 (6%) 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Neurofibroma 1 (2%) Subcutaneous Tissue, Sarcoma 2 (4%) 2 (4%) Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) Cranium, Carcinoma, Metastatic, Harderian Gland 1 (2%) Cranium, Hemangiosarcoma 1 (2%) Skeletal Muscle (2) (3) (1) Hepatocholangiocarcinoma, Metastatic, Liver 1 (33%) Back, Hemangiosarcoma 1 (50%) Diaphragm, Intercostal, Alveolar/Bronchiolar Carcinoma, Multiple, Metastatic, Lung 1 (33%) Head, Carcinoma, Metastatic, Harderian Gland 1 (33%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (49) Adenocarcinoma, Metastatic, Liver 1 (2%) Carcinoma, Metastatic, Harderian Gland 1 (2%) Meninges, Hemangiosarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ Page 11 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) Adenocarcinoma, Multiple, Metastatic, Uncertain Primary Site 1 (2%) Adenocarcinoma, Multiple, Metastatic, Greater Than Five, Liver 1 (2%) Adenocarcinoma, Metastatic, Liver 1 (2%) Alveolar/Bronchiolar Adenoma 7 (14%) 6 (12%) 12 (24%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) Alveolar/Bronchiolar Adenoma, Multiple, Two 1 (2%) 1 (2%) 4 (8%) Alveolar/Bronchiolar Carcinoma 3 (6%) 2 (4%) Carcinoma 1 (2%) Hepatocellular Carcinoma, Multifocal, Metastatic, Greater Than Five, Liver 1 (2%) Hepatocellular Carcinoma, Multiple, Metastatic, Liver 1 (2%) 1 (2%) Hepatocellular Carcinoma, Multiple, Metastatic, Three, Liver 1 (2%) Hepatocellular Carcinoma, Metastatic 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 4 (8%) 2 (4%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Mediastinum, Adenocarcinoma, Metastatic, Liver 1 (2%) Mediastinum, Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Parenchyma, Mediastinum, Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) Parenchyma, Mediastinum, Carcinoma, Multiple, Metastatic, Harderian Gland 1 (2%) Nose (50) (50) (50) Mucosa, Carcinoma, Metastatic, Harderian Gland 1 (2%) Mucosa, Hemangiosarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Ear (1) Glioma Malignant, Metastatic 1 (100%) Eye (1) Carcinoma, Metastatic, Harderian Gland 1 (100%) Harderian Gland (3) (5) Adenoma 3 (100%) 4 (80%) Carcinoma 1 (20%) ____________________________________________________________________________________________________________________________________ Page 12 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (50) Adenocarcinoma, Metastatic, Liver 1 (2%) Alveolar/Bronchiolar Carcinoma, Multiple, Metastatic, Lung 1 (2%) Hepatocellular Carcinoma, Multiple, Metastatic, Liver 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Adventitia, Adenocarcinoma, Metastatic, Liver 1 (2%) Capsule, Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Urinary Bladder (50) (49) (50) Transitional Epithelium, Papilloma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) Lymphoma Malignant Histiocytic 1 (2%) 1 (2%) Lymphoma Malignant Mixed 5 (10%) 11 (22%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 13 NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC FURAN Date: 09/03/94 Route: GAVAGE Time: 02:49:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 8. MG/KG 15. CONTROL MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 43 45 50 Total Primary Neoplasms 75 122 121 Total Animals with Benign Neoplasms 32 38 46 Total Benign Neoplasms 45 57 73 Total Animals with Malignant Neoplasms 19 41 39 Total Malignant Neoplasms 30 65 48 Total Animals with Metastatic Neoplasms 3 10 3 Total Metastatic Neoplasm 3 62 8 Total Animals with Malignant Neoplasms 3 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 14 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------ --multipart-boundary Content-type: text/plain Range: bytes 85204-85204/85204 --multipart-boundary--